Trial Profile

A Phase I/II Study of Azacitidine in Combination With Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Lenalidomide (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

21 Dec 2012 Lenalidomide dosage info conflicting in NCT and 9144642.
10 Dec 2012 Results were presented at the American Society of Hematology annual meeting, according to a Celgene International Sarl media release.
09 Aug 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com